KERNX Health vs EverSlim
A consultation billed per event against one folded into the monthly price.
KERNX Health
Editorial
$129/mo
KERNX Health advertises founding rates of $129 a month for compounded semaglutide and $199 for compounded tirzepatide, against standard rates of $249 and $299 once the founding cohort closes. A provider consultation fee is billed apart from the medication rate and charged only when treatment is approved: $25 for a message-based review, $35 for a standard live visit and $60 for a complex one. Both rates are stated as flat at every dose.
Pick it for: Readers who want three tiers and a one-off consult charge
EverSlim
Editorial
$113/mo
EverSlim prices compounded semaglutide at a flat $113 a month and compounded tirzepatide at a flat $136, with the medication, the provider visit and shipping described as included in both. It reaches fifty states and the District of Columbia. No prepay ladder is published, so nothing has to be bought in advance to reach either rate.
Pick it for: Readers who want no separate consultation line at all
Our verdict
KernX charges a consultation fee that applies on approval rather than every month; EverSlim states its visit is inside the $113. Both are honest arrangements, and they land differently on a first bill.
What actually separates them
KERNX Health and EverSlim state different things about published price. Everything else they publish, they publish the same way.
KERNX Health costs $16 more than EverSlim — 14% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,356 at EverSlim against $1,548 at KERNX Health — a difference of $192.
| KERNX Health | EverSlim | |
|---|---|---|
| Published price | $129/mo | $113/mo |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.